After Gibson Dunn knocked out a derivative suit over Allergan's Botox marketing six months ago, the company and its board hoped the litigation had been put to rest. But Vice Chancellor J. Travis Laster of the Delaware Court of Chancery dashed those hopes on Monday--in an decision that's sure to have lawyers in both the defense and plaintiffs bar gnashing their teeth.
Bad News for Allergan--and First-To-File Plaintiffs--in Delaware Derivative Ruling
The Litigation Daily
June 12, 2012
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.